Previous Close | 5.75 |
Open | 5.35 |
Bid | 4.10 |
Ask | 6.30 |
Strike | 50.00 |
Expire Date | 2023-06-16 |
Day's Range | 5.35 - 5.35 |
Contract Range | N/A |
Volume | |
Open Interest | 480 |
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
Pfizer, BioNTec and Moderna are part of Zacks Analyst top Blog.
Germany's health minister said on Sunday he will push for more prescriptions of Pfizer's oral COVID-19 antiviral treatment Paxlovid by family doctors to reduce severe cases of the disease. "A system involving family doctors will be prepared to administer this far too rarely-used COVID life saver more routinely," he wrote https://twitter.com/Karl_Lauterbach/status/1543582226788634624 on Twitter on Sunday, adding that sufficient stockpiles were available. In his tweet, Lauterbach mentioned trial results that the oral treatment course can cut the risk of hospitalisation in the elderly by 90%, when taken early after infection.